DBTX — Decibel Therapeutics Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeSmall Cap
Brief: Decibel Therapeutics Inc - May Offer, Sell Shares Of Common Stock Of Up To $50 Million From Time To Time Through Jefferies
Brief: Decibel Therapeutics Reports Second Quarter 2022 Financial Results And Corporate Update
U.S. STOCKS ON THE MOVE-Netflix, Playtika, Shopify, Li Auto
Decibel Therapeutics rises on hearing loss treatment study data
Brief: Decibel Therapeutics Reports Positive Data From Interim Analysis Of Ongoing Phase 1B Clinical Trial Of Db-020 In Patients Receiving Cisplatin Chemotherapy
Decibel Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Decibel Therapeutics Reports Q1 Financial Results
Decibel Therapeutics Inc expected to post a loss of 56 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Adobe, Aligos Therapeutics
U.S. RESEARCH ROUNDUP- Adobe, Aligos Therapeutics
Brief: Decibel Therapeutics Inc Files For Mixed Shelf Of Up To $200 Million – SEC Filing
Decibel Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Decibel Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Corporate Update
Decibel up after Regeneron extends collaboration period
U.S. RESEARCH ROUNDUP-Autoweb, Guild Holdings Co, Oceanfirst Financial
Brief: Decibel Therapeutics Reports Third Quarter 2021 Financial Results
U.S. RESEARCH ROUNDUP-BankUnited, Chipotle Mexican Grill, Progress Software
Brief: Decibel Therapeutics Announces Publication Of Foundational Study Of Noise-Related Inner Ear Damage
Brief: Decibel Therapeutics Receives Orphan Drug And Rare Pediatric Disease Designations For Db-Oto For The Treatment Of Otoferlin-Related Congenital Hearing Loss